Vita 34 AG: Expansion of Foreign Business with Partners in Eastern Europe
Vita 34 AG / Key word(s): Alliance Vita 34 AG: Expansion of Foreign Business with Partners in Eastern Europe – Cooperation partner Bio Save expands sales activities in Romania and Croatia – New markets offer additional sales and profit potential for Vita 34 – With more than 95,000 umbilical cord blood preparations stored, the company is the confirmed market leader in the German-speaking countries Leipzig, 08 July 2013 – Vita 34 AG (WKN A0BL84), Europe’s oldest private stem cell bank and specialist for cryo-preservation is expanding its international presence by means of cooperative ventures with the Serbian Bio Save company. Bio Save plans on expanding activities to Romania and Croatia. Thanks to the existing, nearly year-old sales and marketing cooperative venture with Bio Save, Vita 34 is storing umbilical cord blood for customers from Serbia, Montenegro, Macedonia and Bosnia-Herzegovina. Vita 34 expects positive impetus on the number of storages from the planned Bio Save expansion. Moreover, Vita 34 will round out its offering in the East European market with an additional cooperation partner in Bulgaria. Apart from Germany, Vita 34 is active in a total of eleven European countries via subsidiaries and cooperation partners. Within the context of the cooperation, the partner companies are independently responsible for the marketing and sales activities for the storage of umbilical cord blood, and in doing so use the collection kit developed by Vita 34. Vita 34 then readies the umbilical cord blood preparations under observance of the highest quality standards for permanent storage in its own cryo-tanks at its Leipzig headquarters. Dr. André Gerth, Chairman of the Management Board of Vita 34 AG: ‘We are delighted to announce the expansion into these European markets. We have been able to attract accomplished sales partners with Bio Save and also now in Bulgaria. In the medium term we see additional potential for positive effects on revenue and profit in the new markets.’ For example, umbilical cord blood is currently collected and stored in some 11,000 births annually in Romania. Vita 34 expects to be able to achieve a significant market share there. Vita 34 is the market leader in the entire German-speaking region, with more than 95,000 umbilical cord blood preparations stored.
Company Profile Vita 34 was founded in 1997 as the first private umbilical cord blood bank in Europe and, as a complete provider, offers collection logistics, preparation and storage of umbilical cord blood. The basis for its successful work is an outstanding position in the technological segment of cryo-preservation. Here, cells and tissues are preserved alive at temperatures around minus 190 degrees Celsius, and can be used if needed in the context of medical treatment. Parents of more than 95,000 children are already taking advantage of this offering and have provided for their children with a stem cell deposit at this Leipzig company. End of Corporate News 08.07.2013 Dissemination of a Corporate News, transmitted by DGAP – a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. DGAP’s Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
Language: | English | |
Company: | Vita 34 AG | |
Deutscher Platz 5a | ||
04103 Leipzig | ||
Germany | ||
Phone: | +49(0341)48792-40 | |
Fax: | +49(0341)48792-39 | |
E-mail: | ir@vita34.de | |
Internet: | www.vita34.de | |
ISIN: | DE000A0BL849 | |
WKN: | A0BL84 | |
Listed: | Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart | |
End of News | DGAP News-Service |
220161 08.07.2013 |